An ingredient in cannabis may be useful for treating psychosis – new study

December 15, 2017 by Philip Mcguire, The Conversation
Cannabis sativa. Credit: Kojin/Shutterstock.com

Psychiatric patients treated with a substance found in cannabis, cannabidiol, showed a significant reduction in psychotic symptoms and were also more likely to be rated as "improved" by their psychiatrist, our latest study shows.

Psychotic disorders affect two to three per cent of the population. They usually begin in early adulthood and the symptoms can be lifelong. Patients typically experience paranoia, hallucinations and a lack of motivation.

The main treatment for psychosis is , which have been the first line of treatment since the 1950s. These drugs are usually partially effective, but in around a third of patients they don't work at all. They also can have significant side effects.

A new class of treatment

Antipsychotic medications act by blocking dopamine receptors in the brain. However, dopamine is not the only neurotransmitter whose function is altered during psychosis. And, in some patients, dopamine function can even be relatively normal. So there is a need for new drugs that target other neurotransmitter systems that are implicated in psychosis.

Previous research at King's College London has demonstrated that cannabidiol (CBD), a substance found in cannabis, has broadly opposite effects on brain function and on symptoms to the main psychoactive compound in cannabis, delta-9-tetrahydrocannabinol (THC).

Antipsychotic drugs can cause severe side effects. Credit: ANASTASIIAKU/Shutterstock.com

THC is responsible for many of the harmful effects of cannabis, such as paranoia and anxiety, whereas CBD appears to reduce these symptoms. This suggests that CBD might be useful as a treatment for psychosis and other .

Our study, published in the American Journal of Psychiatry, is the first placebo-controlled clinical trial of CBD in patients with psychosis.

We gave 88 patients with psychosis either CBD or a placebo for six weeks alongside their existing antipsychotic medication. Before and after treatment, researchers assessed their level of and the patient's psychiatrist rated their condition overall. Neither the researchers nor the psychiatrists knew whether the patients were receiving CBD or placebo.

There was a reduction in symptoms in the patients treated with CBD, and the clinicians looking after them thought that they had got better. The rate of possible side effects in patients given CBD was no more than in patients who were given the placebo.

While it is still unclear exactly how CBD works, we know that it acts in a different way to antipsychotic medication, so it could represent a new class of . The absence of side effects is also potentially important, as a key problem in caring for with is that they are often reluctant to take antipsychotic drugs because of concerns about side effects.

The next steps are to carry out larger trials of CBD to confirm these initial promising findings, and to assess the effectiveness of CBD in other types of patient.

Explore further: Psychosis in Parkinson's dementia—new treatment provides hope

Related Stories

Psychosis in Parkinson's dementia—new treatment provides hope

September 25, 2017
New research involving King's College London and the University of Exeter has highlighted the benefits of a promising new treatment which could relieve psychosis in thousands of people with dementia related to Parkinson's ...

Marijuana may produce psychotic-like effects in high-risk individuals

September 13, 2017
Marijuana may bring on temporary paranoia and other psychosis-related effects in individuals at high risk of developing a psychotic disorder, finds a preliminary study from researchers at Columbia University Medical Center ...

Benefits of antipsychotics outweigh risks, find experts

May 5, 2017
An international group of experts has concluded that, for patients with schizophrenia and related psychotic disorders, antipsychotic medications do not have negative long-term effects on patients' outcomes or the brain. In ...

Antipsychotics increase risk of death in people with Parkinson's disease psychosis

September 30, 2015
Antipsychotic drugs may increase the risk of death in people with Parkinson's disease psychosis (PDP), according to a new study led by researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's ...

Cannabis abuse possible cause of psychosis

November 8, 2016
The risk of developing psychosis is more than tripled for those who abuse cannabis, according to results from a new twin study.

Dose-dependent link between cannabis use, psychosis relapse

September 29, 2016
(HealthDay)—Cannabis use may raise the risk of psychosis relapse, according to a study published online Sept. 28 in JAMA Psychiatry.

Recommended for you

Early puberty in white adolescent boys increases substance use risk

July 16, 2018
White adolescent boys experiencing early puberty are at higher risk for substance use than later developing boys, a new Purdue University study finds.

How looking at the big picture can lead to better decisions

July 13, 2018
New research suggests how distancing yourself from a decision may help you make the choice that produces the most benefit for you and others affected.

Nature is proving to be awesome medicine for PTSD

July 13, 2018
The awe we feel in nature can dramatically reduce symptoms of post-traumatic stress disorder, according to UC Berkeley research that tracked psychological and physiological changes in war veterans and at-risk inner-city youth ...

Is depression during pregnancy on the rise?

July 13, 2018
(HealthDay)—Today's young mothers-to-be may be more likely to develop depression while pregnant than their own mothers were, a new study suggests.

Machine learning helps to predict the treatment outcomes of schizophrenia

July 12, 2018
Could the diagnosis and treatment of mental health disorders one day be aided through the help of machine learning? New research from the University of Alberta is bringing us closer to that future through a study published ...

Mental illness study to explore patients' self-assessments

July 12, 2018
As the mental health community pursues new ways to improve the lives of the severely ill, a University of Texas at Dallas researcher is focusing on what can be learned from patients' answers to a simple question: "How do ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Anonym
1 / 5 (1) Dec 16, 2017
"Psychotic disorders affect two to three per cent of the population. They usually begin in early adulthood and the symptoms can be lifelong. Patients typically experience paranoia, hallucinations and a lack of motivation."

Paranoia, hallucinations and lack of motivation are, of course, the classic symptoms of THC intoxication.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.